Retatrutide, a new dual agonist of the GLP-1 receptor and glucose-dependent secreted polypeptide (GIP) binding site , is showing promising outcomes in initial human trials . Ongoing research https://bookmarkfly.com/story21366117/retatrutide-emerging-investigations-and-projected-clinical-roles